Market closed

Humacyte/$HUMA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Humacyte

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.

Ticker

$HUMA
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Durham, United States

Employees

184
Website
www.humacyte.com

Humacyte Metrics

BasicAdvanced
$565M
-
-$1.36
1.47
-

$565M

1.47

$9.97

$2.48

6.3M

1.099

0.982

-120.442

-124.974

-13.24%

-53.23%

1,143.87%

-8.26

-8.26

-5.359

56.87%

-37.29%

What the Analysts think about Humacyte

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Humacyte stock.

Humacyte Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Humacyte Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Humacyte News

AllArticlesVideos
Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA

Humacyte, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your Rights - HUMA

Accesswire·9 hours ago
Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc. (HUMA)

Contact Levi & Korsinsky by January 17, 2025 Deadline to Join Class Action Against Humacyte, Inc. (HUMA)

Accesswire·10 hours ago
HUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

HUMA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA

Accesswire·10 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HUMA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Humacyte stock?

Humacyte (HUMA) has a market cap of $565M as of January 15, 2025.

What is the P/E ratio for Humacyte stock?

The price to earnings (P/E) ratio for Humacyte (HUMA) stock is 0 as of January 15, 2025.

Does Humacyte stock pay dividends?

No, Humacyte (HUMA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Humacyte dividend payment date?

Humacyte (HUMA) stock does not pay dividends to its shareholders.

What is the beta indicator for Humacyte?

Humacyte (HUMA) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.